{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390282680165338752.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.4993/acrt.16.21"}},{"identifier":{"@type":"URI","@value":"http://www.jstage.jst.go.jp/article/acrt/16/1/16_1_21/_pdf"}},{"identifier":{"@type":"NAID","@value":"130000119345"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2010041532"}}],"dc:title":[{"@language":"en","@value":"Advanced Pancreatic Cancer Successfully Treated with Biweekly Low-Dose Gemcitabine"}],"dc:language":"en","description":[{"type":"abstract","notation":[{"@language":"en","@value":"A 74-year-old male was admitted to our hospital in August 2006 because of an exacerbation of the symptom of diabetes mellitus. Abdominal CT showed locally advanced cancer of the head of the pancreas with encasement of the superior mesenteric artery, suggesting that the lesion was unresectable. The patient was scheduled for treatment with gemcitabine at the standard dose of 1000 mg/m<sup>2</sup> once a week for 3 consecutive weeks followed by a one week rest, but on day 7 of cycle 1, grade 3 of hematological toxicity was diagnosed, and the schedule was changed to biweekly administration at a dose of 1000 mg/m<sup>2</sup>. The biweekly low-dose gemcitabine regimen slightly reduced tumor size, and the regimen was continued for 12 months. This case suggests that this new biweekly regimen of gemcitabine can be used as a safe and effective first-line chemotherapy for patients with advanced pancreatic cancer who are unable to tolerate the standard regimen of gemcitabine."}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1420001326221403008","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"50276234"},{"@type":"NRID","@value":"1000050276234"},{"@type":"NRID","@value":"9000345402988"},{"@type":"NRID","@value":"9000283663690"},{"@type":"NRID","@value":"9000004230767"},{"@type":"NRID","@value":"9000021934867"},{"@type":"NRID","@value":"9000021911100"},{"@type":"NRID","@value":"9000258620245"},{"@type":"NRID","@value":"9000258073770"},{"@type":"NRID","@value":"9000326658385"},{"@type":"NRID","@value":"9000405885007"},{"@type":"NRID","@value":"9000409315846"},{"@type":"NRID","@value":"9000001138745"},{"@type":"NRID","@value":"9000024407939"},{"@type":"NRID","@value":"9000286628445"},{"@type":"NRID","@value":"9000399230280"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/read0064898"}],"foaf:name":[{"@language":"en","@value":"Kishikawa Hiroshi"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Gastroenterology, Tokyo Dental College Ichikawa General Hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282680165338753","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021934868"}],"foaf:name":[{"@language":"en","@value":"Nishida Jiro"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Gastroenterology, Tokyo Dental College Ichikawa General Hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282680165338755","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021934869"}],"foaf:name":[{"@language":"en","@value":"Inokuchi Sayaka"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Gastroenterology, Tokyo Dental College Ichikawa General Hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282680165338756","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021934870"}],"foaf:name":[{"@language":"en","@value":"Kaida Shogo"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Gastroenterology, Tokyo Dental College Ichikawa General Hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282680165338752","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021934871"}],"foaf:name":[{"@language":"en","@value":"Morishita Tetsuo"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Internal Medicine, Tokyo Dental College Ichikawa General Hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282680165338754","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021934872"}],"foaf:name":[{"@language":"en","@value":"Hibi Toshifumi"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Internal Medicine, School of Medicine, Keio University"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13446835"},{"@type":"EISSN","@value":"18805469"},{"@type":"CODEN","@value":"ACRTCO"}],"prism:publicationName":[{"@language":"en","@value":"Annals of Cancer Research and Therapy"},{"@language":"ja","@value":"Ａｎｎａｌｓ　ｏｆ　Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ　ａｎｄ　Ｔｈｅｒａｐｙ"},{"@language":"en","@value":"Ann. Cancer Res. Therap."},{"@language":"en","@value":"ACRT"},{"@language":"ja","@value":"Ａｎｎａｌｓ　ｏｆ　Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ　ａｎｄ　Ｔｈｅｒａｐｙ"}],"dc:publisher":[{"@language":"en","@value":"The Japanese Society of Strategies for Cancer Research and Therapy"},{"@language":"ja","@value":"日本癌病態治療研究会"}],"prism:publicationDate":"2008","prism:volume":"16","prism:number":"1","prism:startingPage":"21","prism:endingPage":"22"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","url":[{"@id":"http://www.jstage.jst.go.jp/article/acrt/16/1/16_1_21/_pdf"},{"@id":"https://search.jamas.or.jp/link/ui/2010041532"}],"availableAt":"2008","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=pancreatic%20cancer","dc:title":"pancreatic cancer"},{"@id":"https://cir.nii.ac.jp/all?q=gemcitabine","dc:title":"gemcitabine"},{"@id":"https://cir.nii.ac.jp/all?q=biweekly%20administration","dc:title":"biweekly administration"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360574093619122176","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study."}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519221564544","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Phase I Trial of Gemcitabine in Patients with Advanced Pancreatic Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699996301072640","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418479699200","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Phase II study of gemcitabine in patients with advanced pancreatic cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894094108416","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369151276800","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Reporting results of cancer treatment"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370496889216","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107371100146432","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial."}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795884630272","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951796118092032","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study."}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:0031022023"},{"@type":"CROSSREF","@value":"10.4993/acrt.16.21"},{"@type":"CIA","@value":"130000119345"},{"@type":"OPENAIRE","@value":"doi_dedup___::b5ebda0c420b7a96bbba9c2f81195ffa"}]}